Evaluación de la biosimilitud y comparabilidad de medicamentos biosimilares

Article Spanish; Castilian OPEN
Calvo Hernáez, Begoña; Zúñiga Hernando, Leyre; Gómez López-Tello, Paloma;
(2013)
  • Publisher: Universidad de Granada, Facultad de Farmacia
  • Subject: Biosimilares | Comparability | Medicamentos genéricos | Biosimilars | Recombinant proteins | EMA | Proteínas recombinantes | Comparabilidad | Generic medicines

Al finalizar el periodo de patente de los medicamentos de origen biotecnológico, como las proteínas de origen recombinante y los anticuerpos monoclonales, se ha abierto la posibilidad de fabricar copias de dichos fármacos, denominados medicamentos biosimilares. Para con... View more
  • References (7)

    1. Zúñiga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol. 2010; 56:374-7.

    2. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012; 120:5111-7.

    3. European Medicines Agency. Guideline on similar biological medicinal product, EMA (CHMP/437/04). 2004 [citado 15 enero 2013]. Disponible en: http://www.emea. europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003517.pdf

    4. European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1), EMA (CHMP/BWP/247713/2012). 2012 [citado 15 enero 2013]. Disponible en: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2012/05/ WC500127960.pdf

    5. European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMA (CPMP/3097/02). 2003 [citado 15 enero 2013]. Disponible en: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/09/ WC500003963.pdf

    6. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance. Quality issues, EMA (CHMP/ BWP/49348/05). 2006 [citado 15 enero 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2009/09/WC500003953.pdf

    7. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance. non-clinical and clinical issues, EMA (CHMP/BMWP/42832/05). 2006 [citado 15 enero 2013]. Disponible en: http://www.ema.europa.eu/docs/

  • Metrics
Share - Bookmark